Cytokinetics, Incorporated
CYTK
$38.34
$0.290.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.19% | -15.96% | -12.03% | -9.43% | -1.05% |
| Total Depreciation and Amortization | -27.44% | -23.23% | -19.85% | 86.87% | 90.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.86% | 51.43% | 53.14% | 12.98% | -15.15% |
| Change in Net Operating Assets | -115.50% | 1,732.62% | 1,054.55% | 255.63% | 306.98% |
| Cash from Operations | -6.98% | 5.59% | 4.45% | 7.78% | 6.39% |
| Capital Expenditure | -433.45% | -843.79% | -175.85% | 40.74% | 79.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 137.83% | -537.77% | -328.19% | -309.53% | -12,806.61% |
| Cash from Investing | 135.81% | -550.94% | -331.18% | -313.02% | -3,947.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -168.06% | -630.89% | -1,020.98% | -834.68% | 96.99% |
| Issuance of Common Stock | -97.05% | 113.13% | 315.92% | 5,241.68% | 4,740.00% |
| Repurchase of Common Stock | 90.74% | 93.52% | -86.66% | -75.42% | -75.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -70.00% | 300.00% | 300.00% | 161.81% | 847.26% |
| Cash from Financing | -92.24% | 150.26% | 320.49% | 1,231.31% | 175.12% |
| Foreign Exchange rate Adjustments | -3,517.39% | -1,357.14% | 1,145.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.80% | -370.18% | -139.31% | -755.68% | 593.57% |